[Special Stock] Access Bio Expected to Benefit from Antigen Test Kits... "US CDC Cancels PCR Diagnostic Reagents"

[Asia Economy Reporter Yoo Hyun-seok] Access Bio is showing strong performance. It appears to be influenced by the U.S. Centers for Disease Control and Prevention (CDC) announcing the cancellation of Emergency Use Authorization (EUA) for one of the reagents used in genetic amplification testing (RT-PCR) for COVID-19.

As of 11:08 AM on the 28th, Access Bio was trading at 29,650 KRW, up 5.52% (1,550 KRW) compared to the previous trading day.

According to the financial investment industry, on the 21st (local time), the CDC pre-announced its decision to cancel the EUA for one of the diagnostic reagents used in RT-PCR tests to detect COVID-19 (SARS-COV-2). The CDC stated, "After December 31, we will withdraw the EUA request for the COVID-19 real-time RT-PCR diagnostic panel from the U.S. Food and Drug Administration (FDA)."

Access Bio received EUA approval from the FDA in June for its All-In-One COVID-19 antibody rapid diagnostic kit.

Access Bio is also in the process of obtaining U.S. EUA for its COVID-19 antigen self-test kit. It has successfully completed clinical trials and is currently under review by the FDA.